You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Whenever you browse the internet, accept cookies, or download an app ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...